Edition:
India

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

3.25EUR
19 Jan 2018
Change (% chg)

€-0.02 (-0.61%)
Prev Close
€3.27
Open
€3.27
Day's High
€3.28
Day's Low
€3.22
Volume
195,256
Avg. Vol
121,878
52-wk High
€3.30
52-wk Low
€2.37

Latest Key Developments (Source: Significant Developments)

Valneva Expands Its Commercial Operations And Establishes US Infrastructure
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - VALNEVA SE ::REG-VALNEVA EXPANDS ITS COMMERCIAL OPERATIONS AND ESTABLISHES US INFRASTRUCTURE.  Full Article

Valneva 9M EBITDA increases to 12.3 million euros
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - VALNEVA SE ::TOTAL REVENUES OF €79.8 MILLION IN FIRST NINE MONTHS 2017 VERSUS TO €70.7 MILLION YEAR AGO‍​.POSITIVE OPERATING CASH FLOW OF €18.2 MILLION IN THE FIRST NINE MONTHS OF 2017.9M EBITDA OF EUR 12.3 MILLION VERSUS EUR 3.5 MILLION YEAR AGO.NET LOSS IN FIRST NINE MONTHS OF 2017 WAS €7.8 MILLION COMPARED TO NET LOSS OF €46.5 MILLION YEAR AGO.FULL YEAR OUTLOOK LEADS TO UPWARD REVISION OF EBITDA GUIDANCE .INCREASES ITS FULL YEAR EBITDA GUIDANCE TO €10M - €13 MILLION COMPARED TO PREVIOUS GUIDANCE OF €5 - €10 MILLION‍​.  Full Article

Valneva signs contract with US government
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - VALNEVA SE ::ANNOUNCED ON TUESDAY SIGNATURE OF $39.6 MILLION IXIARO SUPPLY CONTRACT WITH US GOVERNMENT.NEW AGREEMENT WILL SUPPLEMENT INITIAL CONTRACT VALNEVA SIGNED WITH THE US MILITARY IN MARCH 2016.VALNEVA WILL SUPPLY IXIARO DOSES OVER A ONE-YEAR PERIOD FOR A VALUE OF $28.2 MLN GUARANTEED AND UP TO $39.6 MLN.FIRST DELIVERIES ARE EXPECTED TO COMMENCE IN THE COMING WEEKS.  Full Article

Valneva H1 EBITDA turns to 4.7 mln euro profit
Wednesday, 31 Aug 2016 

Valneva SE : Reports strong revenue growth and positive EBITDA in H1 2016 . EBITDA improved to 4.7 million euros ($5.2 million) in H1 2016 (versus a loss of 5.3 million euros H1 2015) . H1 revenue 51.4 million euros versus 39.2 million euros year ago . Q2 net loss is 34.4 million euros versus loss of 8.8 million euros a year ago . Re-Affirms its FY 2016 financial outlook .2016 IFRS revenues expected to reach 90-100 million euros, with product sales between 70-80 million euros - reflecting up to 30 pct growth over 2015 product sales.  Full Article

Valneva reports strong revenue growth and positive EBITDA in H1 2016
Wednesday, 31 Aug 2016 

Valneva Se :Valneva reports strong revenue growth and positive EBITDA in H12016.  Full Article

Valneva confirms its growth strategy and financial outlook
Friday, 1 Jul 2016 

Valneva SE : Announces successful outcome of its agm; confirms its growth strategy and financial outlook . Confirmed its FY 2016 financial target of reaching 90 million euros to 100 million euros in revenues and coming close to EBITDA breakeven . Reiterated its strategy to grow revenues to around 250 million euros by 2020 . Expects to find a partner for phase III trial of its clostridium vaccine candidate before end of year . Expects to enter its lyme vaccine candidate in phase I in second half of 2016 . Expects to announce proof-of-concept results for development of a zika vaccine in coming months . Renewed its equity line with Crédit Agricole CIB . New equity line, which replaces a previous instrument expired in May 2016, will enable Valneva to issue up to 5,474,633 new ordinary shares representing up to 7.33 pct of its ordinary share capital .Based on current share price, amount of equity that could be raised through this equity line could reach approximately 11 million euros.  Full Article

Valneva Q1 net result turns to loss of 5.0 million euros
Wednesday, 11 May 2016 

Valneva SE : Q1 total revenues and grants were €24.7 million ($28.11 million) in Q1 2016 (versus €19.5 million in Q1 2015) . Q1 operating loss improved to €2.7 million (versus €3.7 million in Q1 2015) . Q1 net loss was €5.0 million (compared to adjusted net profit of €9.8 million in Q1 2015) . Cash position at €33.4 million at end of March 2016 . Confirms its FY 2016 financial outlook . 2016 IFRS revenues expected to reach €90 to €100 million, with product sales between €70 and €80 million .Says will continue to strive towards financial self-sustainability and expects to reduce its EBITDA loss to less than €5 million in 2016 while continuing to invest around €25 million in R&D.  Full Article

Valneva reports 2016 guidance in line with analysts' estimates
Monday, 21 Mar 2016 

Valneva SE:Expects 2016 overall IFRS revenues to reach 90 to 100 million euros with product sales in expected range of 70 to 80 million euros.FY 2016 revenue: 98.53 million euros - Thomson Reuters I/B/E/S.Company anticipates continued growth of Ixiaro /Jespect sales to approximately 50 million euros in 2016, up from 30.6 million euros in 2015.Improved revenues due to Valneva's new global marketing & distribution network are expected to lead to a gross margin on product sales of approximately 50 pct in 2016.Expects to reduce its EBITDA loss to less than 5 million euros in 2016 while continuing to invest around 25 million euros in research and development.Envisions growing its revenues to approximately 250 million euros in 2020 through existing and future products.Long term company will continue to build on value growth from research and development and anticipates investing at least 20 pct of its revenues annually in an innovative research and development pipeline.  Full Article

Valneva announces $42 mln Ixiaro supply contract with DoD
Wednesday, 16 Mar 2016 

Valneva SE:Valneva announces $42 million IXIARO supply contract with US government.Valneva will supply IXIARO doses to the defense logistics agency (DLA), supply center of the Us Department of Defense.  Full Article

Valneva issues FY 2016 financial guidance
Wednesday, 24 Feb 2016 

Valneva SE:FY 2016 expected gross margin on product sales of about 50 pct.FY 2016 EBITDA loss expected to be reduced to less than 5 million euros.  Full Article

BRIEF-Valneva Expands Its Commercial Operations And Establishes US Infrastructure

* REG-VALNEVA EXPANDS ITS COMMERCIAL OPERATIONS AND ESTABLISHES US INFRASTRUCTURE Source text for Eikon: Further company coverage: (Gdynia Newsroom)